Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
Gritstone Oncology has expanded a phase 2 clinical trial of its personalized cell therapy to include patients with gastric cancer.